Opendata, web and dolomites

CAESAR SIGNED

Developing Therapeutic Antibodies for Pets

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CAESAR project word cloud

Explore the words cloud of the CAESAR project. It provides you a very rough idea of what is the project "CAESAR" about.

owners    ownership    ibd    5k    12    veterinary    relieve    biotech    treat    diseases    therapies    suffering    put    synthetic    companion    animal    causes    2018    phage    synthesize    spend    40    human    reliance    ge    demonstrated       untenable    expensive    15m    royalties    overcome    inflammatory    team    demographic    native    german    worth    dogs    launch    adivo    specializing    therapy    sufficiently    antibodies    2016    distress    species    pay    generating    severe    scalable    chronic    cancer    ease    companions    licensing    affordable    gt    complete    cagr    inflammation    pets    financial    people    library    400    shifts    antibody    2million    poorly    bowel    expanding    managed    causing    caesar    solution    ineffective    revenue    hire    generate    pet    therapeutics    market    founded    company    animals    first    canine    29bn    3k    therapeutic    immunogenic    emotional    health    global    medical    medicine    display   

Project "CAESAR" data sheet

The following table provides information about the project.

Coordinator
ADIVO GMBH 

Organization address
address: AM KLOPFERSPITZ 19
city: PLANEGG
postcode: 82152
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ADIVO GMBH DE (PLANEGG) coordinator 50˙000.00

Map

 Project objective

Chronic inflammatory diseases in pets such as Inflammatory Bowel Diseases (IBD) are poorly managed causing emotional and financial distress to pet owners. Current therapies are ineffective - they do not relieve pet suffering and lead to the animal being put down. Therapies are also expensive with costs up to €400/month. Antibody therapy for such conditions has long been used in human medicine but has not been sufficiently developed for veterinary medicine and causes an immunogenic response as the antibodies are not species specific. Antibodies need to be adapted which is expensive and causes severe side effects making them an untenable solution at present. Pet ownership in the EU has been on the increase (up by 2million pets since 2016) due to demographic shifts and a greater reliance on pets as companions. The global animal health market is worth > €29Bn growing at a CAGR of 6% with pet health making up 40% of the market. Pet owners spend €3k - €5k/ year on their pet’s health and are willing to pay to ease pet suffering. adivo is a German biotech company specializing in generating species-specific therapeutic antibodies for companion animals. adivo was founded in 2018. The adivo-team aims to address medical needs in dogs including cancer and chronic inflammation, with the potential of expanding activities into the development of therapeutics for other species in future. adivo has developed CAESAR, the first of a kind synthetic canine phage-display library to generate therapeutic antibodies for dogs. We have developed a complete library from which we can synthesize therapeutic antibodies native to treat IBD. Our solution will overcome the challenges of current therapies and provide an affordable, scalable solution for effective antibody therapy for pets which has been demonstrated in human medicine. We expect to generate out-licensing revenue ≥€15M when we launch the product before royalties and hire 12 people.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAESAR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAESAR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Cancersensing (2019)

A multi-cancer screening platform for fast and accurate early stage cancer detection from urine samples

Read More  

EDITUS (2019)

Helping our customers to design smart and safe tomorrows’ communication systems

Read More